# Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.

> **NCT05246293** · PHASE2 · UNKNOWN · sponsor: **National Institute of Respiratory Diseases, Mexico** · enrollment: 60 (estimated)

## Conditions studied

- Rheumatoid Arthritis
- Interstitial Lung Disease

## Interventions

- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT05246293
- **Lead sponsor:** National Institute of Respiratory Diseases, Mexico
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-08
- **Primary completion:** 2024-03-02
- **Final completion:** 2025-03-02
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05246293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05246293, "Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05246293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*